Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England

Overview

Journal J Diabetes Sci Technol

Specialty Endocrinology

Date 2018 Apr 24

PMID 29681171

Citations 5

Authors

Robert Brett McQueen

Marc D Breton

Joyce Craig

Hayden Holmes

Melanie D Whittington

Markus A Ott

Jonathan D Campbell

Affiliations

Soon will be listed here.

Abstract

Objective: The objective was to model clinical and economic outcomes of self-monitoring blood glucose (SMBG) devices with varying error ranges and strip prices for type 1 and insulin-treated type 2 diabetes patients in England.

Methods: We programmed a simulation model that included separate risk and complication estimates by type of diabetes and evidence from in silico modeling validated by the Food and Drug Administration. Changes in SMBG error were associated with changes in hemoglobin A1c (HbA1c) and separately, changes in hypoglycemia. Markov cohort simulation estimated clinical and economic outcomes. A SMBG device with 8.4% error and strip price of £0.30 (exceeding accuracy requirements by International Organization for Standardization [ISO] 15197:2013/EN ISO 15197:2015) was compared to a device with 15% error (accuracy meeting ISO 15197:2013/EN ISO 15197:2015) and price of £0.20. Outcomes were lifetime costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).

Results: With SMBG errors associated with changes in HbA1c only, the ICER was £3064 per QALY in type 1 diabetes and £264 668 per QALY in insulin-treated type 2 diabetes for an SMBG device with 8.4% versus 15% error. With SMBG errors associated with hypoglycemic events only, the device exceeding accuracy requirements was cost-saving and more effective in insulin-treated type 1 and type 2 diabetes.

Conclusions: Investment in devices with higher strip prices but improved accuracy (less error) appears to be an efficient strategy for insulin-treated diabetes patients at high risk of severe hypoglycemia.

Citing Articles

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.

Sacks D, Arnold M, Bakris G, Bruns D, Horvath A, Lernmark A Diabetes Care. 2023; 46(10):e151-e199.

PMID: 37471273 PMC: 10516260. DOI: 10.2337/dci23-0036.

Clinical Study of a High Accuracy Green Design Blood Glucose Monitor Using an Innovative Optical Transmission Absorbance System.

Moriuchi T, Otaki Y, Satou H, Chai F, Hayashida Y, Aikawa R J Diabetes Sci Technol. 2021; 16(5):1069-1075.

PMID: 34889119 PMC: 9445325. DOI: 10.1177/19322968211060865.

Toward a Framework for Outcome-Based Analytical Performance Specifications: A Methodology Review of Indirect Methods for Evaluating the Impact of Measurement Uncertainty on Clinical Outcomes.

Smith A, Shinkins B, Hall P, Hulme C, Messenger M Clin Chem. 2019; 65(11):1363-1374.

PMID: 31444309 PMC: 7055686. DOI: 10.1373/clinchem.2018.300954.

Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.

Fritzen K, Basinska K, Stautner C, Braun K, Rubio-Almanza M, Nicolucci A J Diabetes Sci Technol. 2019; 14(2):262-270.

PMID: 31387385 PMC: 7196878. DOI: 10.1177/1932296819864665.

Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management.

Fritzen K, Basinska K, Rubio-Almanza M, Nicolucci A, Kennon B, Verges B J Diabetes Sci Technol. 2019; 13(6):1112-1122.

PMID: 30917691 PMC: 6835181. DOI: 10.1177/1932296819835172.

References

Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati F, Powe N . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141(6):421-31. DOI: 10.7326/0003-4819-141-6-200409210-00007. View

McQueen R, Ellis S, Campbell J, Nair K, Sullivan P . Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011; 9:13. PMC: 3180394. DOI: 10.1186/1478-7547-9-13. View

Hayes A, Leal J, Gray A, Holman R, Clarke P . UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013; 56(9):1925-33. DOI: 10.1007/s00125-013-2940-y. View

Miller K, Beck R, Bergenstal R, Goland R, Haller M, McGill J . Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013; 36(7):2009-14. PMC: 3687326. DOI: 10.2337/dc12-1770. View

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D . Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013; 16(2):231-50. DOI: 10.1016/j.jval.2013.02.002. View

Schnell O, Erbach M, Wintergerst E . Higher accuracy of self-monitoring of blood glucose in insulin-treated patients in Germany: clinical and economical aspects. J Diabetes Sci Technol. 2013; 7(4):904-12. PMC: 3879755. DOI: 10.1177/193229681300700413. View

Breton M, Kovatchev B . Impact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study. J Diabetes Sci Technol. 2010; 4(3):562-70. PMC: 2901032. DOI: 10.1177/193229681000400309. View

Baxter M, Hudson R, Mahon J, Bartlett C, Samyshkin Y, Alexiou D . Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabet Med. 2016; 33(11):1575-1581. DOI: 10.1111/dme.13062. View

Menzin J, Korn J, Cohen J, Lobo F, Zhang B, Friedman M . Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010; 16(4):264-75. PMC: 10437724. DOI: 10.18553/jmcp.2010.16.4.264. View

10.

Otto S, Nitsche K, Jung C, Gassdorf J, Janiak F, Goebel B . Determinants of neointimal proliferation and stent coverage after intracoronary therapy with drug-eluting devices in stable coronary artery disease: role of endothelial progenitor cells and interleukin-1 family cytokines. J Invasive Cardiol. 2014; 26(12):648-53. View

11.

Eastman R, Javitt J, Herman W, Dasbach E, Maier W, Dong F . Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997; 20(5):735-44. DOI: 10.2337/diacare.20.5.735. View

12.

Wu S, Sainfort F, Tomar R, Tollios J, Fryback D, Klein R . Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care. 1998; 21(5):725-31. DOI: 10.2337/diacare.21.5.725. View

13.

Briggs A . Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000; 17(5):479-500. DOI: 10.2165/00019053-200017050-00006. View

14.

Stevens R, Kothari V, Adler A, Stratton I . The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001; 101(6):671-9. View

15.

McQueen R, Ellis S, Maahs D, Anderson H, Nair K, Libby A . Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205. DOI: 10.1007/s40271-014-0045-4. View

16.

Stahl J . Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics. 2008; 26(2):131-48. DOI: 10.2165/00019053-200826020-00004. View

17.

Cusick M, Meleth A, Agron E, Fisher M, Reed G, Knatterud G . Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care. 2005; 28(3):617-25. DOI: 10.2337/diacare.28.3.617. View

18.

Menzin J, Friedman M, Boulanger L, Cavanaugh R . Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001; 24(1):51-5. DOI: 10.2337/diacare.24.1.51. View

19.

Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A . Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. Diabet Med. 2013; 31(4):477-86. DOI: 10.1111/dme.12371. View

20.

McQueen R, Breton M, Ott M, Koa H, Beamer B, Campbell J . Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. J Diabetes Sci Technol. 2015; 10(2):366-77. PMC: 4773951. DOI: 10.1177/1932296815599551. View